SGEM#518: What Have You Done for Me Lately – Oseltamivir for Hospitalized Patients?

Oseltamivir fails to improve 90-day survival in critically ill patients with laboratory-confirmed influenza, according to a recent international, randomized, adaptive platform trial. Contrary to existing CDC and WHO guidelines that advocate for early antiviral treatment, this study reveals no clinical benefit and identifies a concerning signal for increased mortality in patients requiring respiratory or cardiovascular organ support. While the trial’s open-label design and baseline imbalances necessitate cautious interpretation, the absence of demonstrated efficacy undermines the rationale for routine administration in severe cases. Clinicians should move away from automatic, protocol-driven prescribing, instead utilizing multidisciplinary team discussions and shared decision-making to weigh the lack of proven benefit against potential harms. This evidence shifts the burden of proof, suggesting that Oseltamivir should not be standard practice for patients already receiving intensive care-level support.